Welcome back to the Digital Rheumatology Network podcast, where we dive into the transformative world of digital health in rheumatology. Our latest ‘Insights’ episode takes you behind the scenes of the 6th Digital Rheumatology Days, hosted in Berlin on March 8th and 9th, 2024.

 

In this episode, we’re joined by Mike Rosenbluth, CEO of Swing Therapeutics, discussing the FDA clearance journey for “Stanza,” a new digital therapeutic for Fibromyalgia. Alongside, Prof. Stephen Gilbert from Dresden Technical University shares his expertise in medical device regulatory science. They explore the challenges of bringing such innovations from clinical studies and evaluations to market, considering both U.S. and European regulatory frameworks. This conversation is a must-listen for those interested in the intersection of digital health solutions and regulatory pathways.

Stephen Gilbert is Professor of Medical Device Regulatory Science at the Else Kröner Fresenius Center for Digital Health, Technische Universität Dresden where he teaches and conducts research on regulatory science with a team of colleagues. He worked in senior MedTech and Digital Heath roles in industry for 5 years, before returning to academia in 2022.

Mike Rosenbluth, PhD, is the founder and CEO of Swing Therapeutics. Swing develops digital therapeutics and is a telehealth platform for fibromyalgia and other primary pain and rheumatologic diseases. Mike holds a Doctorate Degree in biomedical engineering from UC Berkeley and UCSF and a BS and MS degree in mechanical engineering from Stanford University. He has been dedicated throughout his career to translating innovation in healthcare with a focus on delivering better care for underserved diseases. 

Interview with Prof Stephen Gilbert & Dr. Mike Rosenbluth

by Marc Blanchard

If you like to get more intersting content please become a member or if you are already a member go to the member area directly: